Home
Cell & Gene Therapy
10 October - 11 October 2018
Cell & Gene Therapy

SAE Media Group introduces UK & Europe's launch conference; Cell and Gene Therapy, which takes place between the 10th and 11th October 2018.

Cell and gene therapeutics have revolutionised modern medicine and mark a new generation in biomedical and agricultural sciences. The latest developments in cell and gene therapies and specifically in gene editing technologies present unlimited research opportunities ranging from novel therapeutic tools to a potential revolution in the field of drug discovery.

This year event will be led by scientists and clinicians researching, developing and testing new treatments for genetically inherited and acquired diseases using gene delivery technology, stem cell manipulation and DNA repair techniques. The conference will cover all aspects of the subject, including biomedical science principles, molecular basis of disease, current and developing technologies and clinical applications.

Join our expert speaker panel at the Cell and Gene Therapy conference to ensure you do not miss out on the latest developments! Presenting new technologies, specific case studies, updates on GMP, MHRA regulatory guidelines, quality control and therapeutic applications of stem cells, pre-clinical and clinical trial design, advanced cell engineering technologies, commercialisation of ATMPs, global pricing, ethical overviews and many more.

FEATURED SPEAKERS

Diego Ardigo

Diego Ardigo

R&D Rare Disease Unit Head, Chiesi Farmaceutici S.p.A.
Emanuela Cuomo

Emanuela Cuomo

Associate Director, AstraZeneca
Ian McKay

Ian McKay

Innovation Lead, Advanced Therapies, Innovate Uk
Janet Glassford

Janet Glassford

Quality Assessor , Medicines and Healthcare Products Regulatory Agency (MHRA)
Kei Kishimoto

Kei Kishimoto

Chief Scientific Officer, Selecta Biosciences Inc.
Lior  Raviv

Lior Raviv

Vice President of Development, Pluristem
Mehdi  Gasmi

Mehdi Gasmi

Chief Science and Technology Officer, Adverum Biotechnology
Pamela Tranter

Pamela Tranter

Head of Translational Research Group, UCL
Peggy Sotiropoulou

Peggy Sotiropoulou

R&D Manager, Celyad
Shailesh Gupta

Shailesh Gupta

Senior Scientist, AstraZeneca PLC
Yen Choo

Yen Choo

Founder and Executive Chairman, Plasticell

Diego Ardigo

R&D Rare Disease Unit Head, Chiesi Farmaceutici S.p.A.
Diego Ardigo

Dr. Ardigò is an MD (Internal Medicine) and obtained his PhD at the University of Parma (Italy) and his post-doctoral fellowship at Stanford University (California, US). Before joining the industry, he worked at the University of Parma (Italy) in the field of cardiovascular and metabolic genomics and as free-lance consultant for other academic institutions. He joined Chiesi in 2010, where acted as Clinical Lead in the registration of the first stem cell therapy in EU and led the cross-company team (with uniQure BV) treating the first patient with a commercial gene therapy in EU. He is currently the Head of the R&D Rare Disease Unit in Chiesi and chairman of the Therapies Scientific Committee of IRDiRC (International Rare Diseases Research Consortium) and member of EBE-EFPIA ATMP Working Group. He is author of more than 40 indexed papers and speaker at international medical and industrial congresses.

EJ Brandreth

Vice President, Inovio Pharmaceuticals
EJ Brandreth

Emanuela Cuomo

Associate Director, AstraZeneca
Emanuela Cuomo

Emanuela Cuomo is an Associate Director in the Discovery Biology department in Cambridge. She leads the Cell Biology team and co-leads the Precise genome editing discipline contributing to innovation in the CRISPR field. The Cell biology team generated cell models for target identification and validation for the Oncology disease area, including Immuno Oncology.


Emanuela is an expert in the study of cell cycle signaling in normal and cancer cells.


She obtained a PhD in biochemistry at the Institute of Cancer Research in London where she characterised a novel viral cyclin/CDK complex, its modulation by CDK inhibitors and its biological function in oncogenesis. Subsequently she joined UCL Cancer Institute in London in the Viral Oncogenesis team as a CR-UK postdoctoral fellow. There, she studied the interplay between the cellular DNA damage response and viral protein kinases.
 

Ian McKay

Innovation Lead, Advanced Therapies, Innovate Uk
Ian McKay

Ian joined Innovate UK from the Department of Health (DH) where he was the policy lead for stem cell transplantation and advanced therapies. At DH was part of a high profile policy team with a broad scientific remit that included; rare diseases, genomics and emerging technologies. Before joining the DH he was a health and science policy adviser for the British Dental Association. He began his career as a lecturer in cell and molecular biology at Queen Mary, University of London. Ian has a PhD in Developmental Biology.

Ioannis Papantoniou

ATMP Bioprocessing Coordinator, KU Leuven
Ioannis Papantoniou

Ioannis Papantoniou is A Chemical Engineer by training, at the University of Patras, Greece. After graduation he pursued a Doctoral degree (MPhil and PhD) at the Department of Biochemical Engineering, University College London (UCL), UK. He carried out his postdoctoral research activities first at UCL and subsequently at KU Leuven working on bioprocess optimization for prostate cancer cell therapy vaccine production (a precursor of CAR-T cell therapies), in collaboration with Onyvax and skeletal ATMP bioprocess development respectively. Currently he is leading several academic research projects and collaborative R&D activities with several industrial partners active in the cell therapy and tissue engineering, biosensor, and bioreactor sectors. His research aim is to develop automated, scalable and cost-effective bioprocess pipelines for the production of compliant 3D Tissue Engineered ATMPs with built-in quality attributes.

Janet Glassford

Quality Assessor , Medicines and Healthcare Products Regulatory Agency (MHRA)
Janet Glassford

Janet Glassford is a Senior Quality Assessor at the MHRA and an EMA expert, with a special interest in ATMPS. Her role includes assessment of ATMP marketing authorisations, as well as the provision of EMA and MHRA scientific advice and innovation queries. Prior to becoming a regulator, she was an academic fellow at University College London with a research interest in the cell biology of haematological malignancies.

Kei Kishimoto

Chief Scientific Officer, Selecta Biosciences Inc.
Kei Kishimoto

Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology. Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease. Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provided the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim. Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.

Lior Raviv

Vice President of Development, Pluristem
Lior  Raviv

Lior Raviv joined Pluristem in 2011 and currently serves as Vice President of Development. Prior to that Mr. Raviv served as Process development engineer and Projects manager & Product development Team leader at Pluristem in charge of new technologies and process development. Prior to joining Pluristem and during the years 2010-2011, Mr Raviv held the position of R&D Analytical Researcher at Teva Pharmaceutical Industries. Mr. Raviv holds a M.Med.Sec in pharmacology from the Ben Gurion University and a B.S.c, in Biotechnology engineering from the Ben Gurion University.

Mehdi Gasmi

Chief Science and Technology Officer, Adverum Biotechnology
Mehdi  Gasmi

Mehdi Gasmi, Ph.D. is Adverum’s chief science and technology officer. He joined the Company in 2013 and leads process development, manufacturing, and quality control functions for Adverum’s gene therapy product candidates. He is also responsible for the development of Adverum’s novel vector technology platform. A gene therapy veteran, Dr. Gasmi has worked in the field since 1996 at various academic institutions, including City of Hope and the University of California, San Diego, and at gene therapy companies, including Chiron, Cell Genesys, and Ceregene. Dr. Gasmi has extensive experience in the design, development and manufacturing of lentiviral and recombinant AAV vectors for clinical applications. Prior to Adverum, Dr. Gasmi was vice president of biomanufacturing at Généthon. He received a M.S. and Ph.D. in Biochemistry from the Claude Bernard University in Lyon, France.

Pamela Tranter

Head of Translational Research Group, UCL
Pamela Tranter

Pamela joined the UCL Translational Research Office in Nov 2014 and became head of the Translational Research group in Sept 2016. The TRO builds on an increasingly vibrant translational culture across UCL by collaboration with academics, industry partners and external funding bodies, to facilitate the translation of UCL’s emerging research into therapies and medical products. Pamela has advised and supported successful applications for cell and gene therapy projects which she is now managing in both the pre-clinical and early clinical phases.

Prior to this Pamela gained extensive experience of drug discovery in the pharmaceutical industry at Novartis/Ciba-Geigy. She has led projects for multiple small molecule and Biologics targets for respiratory and thrombosis indications.
 

Paul Lloyd-Evans

Operations Manager, NHSBT
Paul Lloyd-Evans

Head of NHSBT’s Clinical Biotechnology Centre since 2007 and responsible for the day to day management of the facility. The CBC is part of NHSBT’s Cell and Molecular Therapies function and specialises in the small scale GMP manufacture of clinical grade gene therapy such as plasmid DNA and recombinant protein products. Graduated in 1984 before undertaking a PhD in Immunology and further post-doctoral studies. In 1993 joined NHSBT in antibody engineering and became the development scientist at the CBC in 2001. To date publications include 24 peer-reviewed papers and articles.

Peggy Sotiropoulou

R&D Manager, Celyad
Peggy Sotiropoulou

Peggy Sotiropoulou is R&D Manager in Celyad, in charge of developing the new strategies in CAR T cell design. Peggy is an expert in tumour initiation, growth and resistance to therapy, tumour microenvironment and cancer stem cells. She has a 17-year career in academic research in oncology, holding an associate Professor position in the Université Libre de Bruxelles, in Brussels, Belgium. Peggy decided to join Celyad in 2017 to translate cutting-edge research and innovation into actual treatments for patients.

Ryan McCoy

Lead Technical Scientist, The Cell and Gene Therapy Catapult
Ryan McCoy

Shailesh Gupta

Senior Scientist, AstraZeneca PLC
Shailesh Gupta

Shailesh is Associate Principle Scientist in Discovery Sciences iMED, AstraZeneca based in Sweden. Shailesh has been using CRISPR/Cas9 and human iPS cells to generate cellular models to understand disease biology and drive drug discovery projects in cardiovascular, metabolic & CNS diseases. Before joining AstraZeneca Shailesh was in Singapore, working for GlaxoSmithKline (GSK), in a group that was focused on modeling CNS diseases & developing novel assays using Stem Cells & iPSCs. Shailesh has a strong background in genome editing, cell based high content small molecule screening, assay development and human stem cells/iPSCs based disease modeling. Previous to his position at GSK, Shailesh was postdoc at Harvard University performing research focused on developing novel therapeutics for ALS disease through high content small molecule screen using motor neurons derived from embryonic stem cells. Shailesh has a PhD in developmental neuroscience

Steven Kanner

Chief Scientific Officer, Caribou Biosciences, Inc.
Steven Kanner

Steve Kanner is the Chief Scientific Officer of Caribou Biosciences responsible for the Company’s therapeutic discovery and R&D activities. Before joining Caribou, Steve was Vice President, Head of Biology at Arrowhead Pharmaceuticals, and worked in oncology and immunology drug discovery at Bristol-Myers Squibb, Agensys/Astellas, and Astex Pharmaceuticals. Steve has authored over 80 publications, and is an inventor on numerous U.S. and foreign patents. Steve earned his undergraduate degree in Genetics from the University of California, Berkeley, and his Ph.D. in Immunology and Microbiology from the University of Miami School of Medicine. His post-doctoral fellowship was at the University of Virginia.

Yen Choo

Founder and Executive Chairman, Plasticell
Yen Choo

Dr Choo is Executive Chairman of Plasticell Ltd and Chief Executive of Progenitor Labs Ltd. He is the founder of Plasticell and served as Chief Executive and Chief Scientist of the company. Prior to his interest in stem cells he was a founder and Chief Scientist of Gendaq (acquired by Sangamo Biosciences), a biotech company that developed the zinc finger technology now used for gene editing. Previously he was a staff scientist at the MRC Laboratory of Molecular Biology, Cambridge, where he pioneered the engineering of protein-DNA interactions using combinatorial methods under Nobel laureate Sir Aaron Klug. Dr Choo holds a PhD in Molecular Biology from the University of Cambridge and for his thesis received the Prize for Young Scientists awarded by GE Healthcare and Science (1996), and the Max Perutz Student Prize awarded by MRC-LMB (1995). He sits on the UK Stem Cell Steering Committee which oversees national stem cell research and the UK Stem Cell Bank.

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Pamela Tranter, Head of Translational Research Group, UCL

clock

9:10

Mitigating the immunogenicity of AAV gene therapy vectors with tolerogenic nanoparticles

Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences Inc.

• Cellular and humoral immunity against AAV can affect the safety and efficacy of gene therapy and the ability to re-treat patients later in life
• We have developed synthetic vaccine particles encapsulating rapamycin (SVP-Rapamycin) that have been shown to mitigate immunogenicity against a variety of biologic drugs by inducing tolerogenic dendritic cells and antigen-specific regulatory T cells
• We will present pre-clinical data demonstrating the ability of SVP-Rapamycin to inhibit the formation of anti-AAV antibodies and share data from an ongoing clinical trial of SVP-Rapamycin combined with a therapeutic enzyme
 

clock

9:50

Becoming cell therapy makers - Opportunities and challenges in “in house” manufacturing of cell therapy products

Lior Raviv, Vice President of Development, Pluristem

  • Reproducible manufacturing techniques  - the basics of process development
  • The importance of closed and automated manufacturing technologies
  • Data management for improvement of process understanding and control
  • The importance of raw materials management
     
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Uk and EU regulatory affairs: the MHRA perspective

    Janet Glassford, Quality Assessor , Medicines and Healthcare Products Regulatory Agency (MHRA)

    • What support is available for companies from early in the development process?
    • Designing clinical trials in a way that comes up with the evidence regulators need to accelerate ATMPs
    • Ensuring safety while reducing cost of development: working together with regulators to make the approval process more efficient
    • Impact of Brexit and further initiatives
     

    clock

    11:40

    Opportunities and Challenges of Translating Cell and Gene Therapies in Academia

    Pamela Tranter, Head of Translational Research Group, UCL

    • Review of the exciting and diverse pipeline of cell and gene therapy projects within UCL with example case studies.
    • Opportunities for project funding:   internal, public funds, industry partners and University spin outs.
    • Understanding the de-risking and evidence required to support the commercial route forward.
     

    clock

    12:20

    Networking Lunch

    clock

    13:20

    Intravitreal rAAV gene therapy approaches for the treatment of retinal disorders

    Mehdi Gasmi, Chief Science and Technology Officer, Adverum Biotechnology

    • Indications that are currently pursued at Adverum Biotechnologies
    • Development of novel AAV capsid targeting the eye
    • Advantages of gene therapy approaches to retinal disorders
     

    clock

    14:00

    Targeting solid and liquid malignancies with the same CAR

    Peggy Sotiropoulou, R&D Manager, Celyad

    • What is an ideal target for CAR T cell therapy?
    • Challenges in targeting solid tumours using CAR T cells
    • Autologous versus allogeneic CAR T cells
     

    clock

    14:40

    Afternoon Tea

    clock

    15:10

    Spotlight: Risk-based approaches to Cell & Gene therapy manufacturing

    Ryan McCoy

    Ryan McCoy, Lead Technical Scientist, The Cell and Gene Therapy Catapult

    • The value of risk and cost based tools in supporting manufacturing development planning
    • Logistics-by-design, introducing a framework built on quality by design principles to support therapy developers in planning their commercial logistics strategy. 
     

    clock

    15:50

    Next-generation gene editing technology for allogeneic immune cell therapeutics

    Steven Kanner, Chief Scientific Officer, Caribou Biosciences, Inc.

    • Next-generation CRISPR-Cas9 technology
    • Significantly enhanced editing specificity
    • Editing in immune cells for generation of functionally tuned therapeutics
     

    clock

    16:30

    Chairman’s Closing Remarks and Close of Day One

    Pamela Tranter, Head of Translational Research Group, UCL

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Ian McKay, Innovation Lead, Advanced Therapies, Innovate Uk

    clock

    9:10

    Spotlight: Advances in cell therapy process development and optimisation at Plasticell

    Yen Choo, Founder and Executive Chairman, Plasticell

    • Combinatorial screening of parameter space for process development and optimisation in cell and gene therapy
    • Expansion of hematopoietic stem cells from cord blood for allogeneic transplantation
    • Enhancement of viral transduction efficiency for autologous gene therapy to treat rare diseases
     

    clock

    9:50

    Generation of endogenous reporter iPS cell lines for optimizing differentiation protocols, understanding disease biology & driving drug discovery projects

    Shailesh Gupta, Senior Scientist, AstraZeneca PLC

    -    CRISPR/Cas9 in engineering iPS cells to generate cellular reagents for drug discovery.
    -    Clone screening capabilities/methodologies.
    -    Characterization, validation & potential application of PGE modified iPS cell lines.
     

    clock

    10:30

    Morning Coffee

    clock

    11:00

    Supporting advanced therapies - the Innovate UK perspective

    Ian McKay, Innovation Lead, Advanced Therapies, Innovate Uk

    • Support for advanced therapies – from Innovate UK and across Government
    • Innovate UK support for the commercialisation of advanced therapies
    • How the Advanced Therapy Treatment Centres will enable adoption of advanced therapies in the NHS
     

    clock

    11:40

    Harnessing CRISPR/Cas9 for drug development

    Emanuela Cuomo, Associate Director, AstraZeneca

    • Genome editing for target identification
    • Genome editing for cell model generation and target validation
    • Genome editing to understand drug resistance
    • Genome editing as a therapeutic
     

    clock

    12:20

    Networking Lunch

    clock

    13:20

    Accessing patients with commercial advanced therapies

    Diego Ardigo, R&D Rare Disease Unit Head, Chiesi Farmaceutici S.p.A.

    • Addressing market access and reimbursement of advanced therapies (ATMPs)
    • Logistics and restricted access programs constraints in bringing ATMPs to patients in a commercial setting
    • Rare disease patient access with ATMPs
     

    clock

    14:00

    GMP manufacture of plasmid DNA

    Paul Lloyd-Evans, Operations Manager, NHSBT

    • Good plasmid DNA manufacturing practice begins with an appropriate vector design. The eukaryotic promoter, gene sequence, and poly-A site primarily affect the therapeutic efficacy, remaining part of the vector is important for manufacturing
    • Choice of the plasmid’s origin of replication (ori) is critical for the plasmid copy number and for the cultivation titer. ColE1-derived, high copy-number pUC ori is widely established due to high copy number. Introduction of random or defined mutations into the pUC ori can further increase the plasmid yield.
    • Selecting appropriate host strain, maximizing titer by upstream optimization, and achieving superior performance in small- and large-scale cGMP manufacturing.
     

    clock

    14:40

    Afternoon Tea

    clock

    15:10

    Downstream benefits of DNA plasmids, plasmid delivery, and recent quality developments in plasmid manufacturing and testing

    EJ Brandreth

    EJ Brandreth, Vice President, Inovio Pharmaceuticals

    • DNA Plasmids have recently emerged as a potent new weapon, acting both as a therapeutic and as a vaccine
    • Plasmid GMP manufacturing, when compared to conventional mammalian and viral approaches, has notable benefits in compliance, cost and in facility throughput, and these will be explored
    • Recent advances in Plasmid testing, especially in light of current Plasmid guidance and recent assay developments, sheds a new light on today’s analytical approaches for process-related impurities, purity and potency for plasmids
     

    clock

    15:50

    Scalable production of adult progenitor cell populations for skeletal regeneration – bridging the gap

    Ioannis Papantoniou, ATMP Bioprocessing Coordinator, KU Leuven

    • Comparison across bioreactor systems -  visualization tools for bioprocess efficiency
    • Evaluation of functionality of expanded cell populations in small animal models – setting the target quality profiles
    • Development of real-time decision-making tools for optimising bioprocess management for high-risk autologous production
    • Adding a third dimension - controlling complexity in tissue engineered ATMPs
     

    clock

    16:30

    Chairman’s Closing Remarks and Close of Day Two

    Ian McKay, Innovation Lead, Advanced Therapies, Innovate Uk


    R&D Rare Disease Unit Head
    Chiesi Farmaceutici S.p.A.
    Vice President
    Inovio Pharmaceuticals
    Associate Director
    AstraZeneca
    Innovation Lead, Advanced Therapies
    Innovate Uk
    ATMP Bioprocessing Coordinator
    KU Leuven
    Quality Assessor
    Medicines and Healthcare Products Regulatory Agency (MHRA)
    Chief Scientific Officer
    Selecta Biosciences Inc.
    Vice President of Development
    Pluristem
    Chief Science and Technology Officer
    Adverum Biotechnology
    Head of Translational Research Group
    UCL
    Operations Manager
    NHSBT
    R&D Manager
    Celyad
    Lead Technical Scientist
    The Cell and Gene Therapy Catapult
    Senior Scientist
    AstraZeneca PLC
    Chief Scientific Officer
    Caribou Biosciences, Inc.
    Founder and Executive Chairman
    Plasticell

    Supporters

    Attendee List

    Download

    [SPEAKER INTERVIEW] - JANET GLASSFORD, MHRA

    Download

    [Chair's Letter 2018] - Pamela Tranter, UCL

    Download

    [SPEAKERS 2018] - FULL LIST OF SPEAKERS

    Download

    [SPEAKER INTERVIEW] - Peggy Sotiropoulou, Ceylad

    Download

    [SPEAKER INTERVIEW] - IOANNIS PAPANTONIOU, KU Leuven

    Download

    [DAY 2] - FULL PROGRAMME

    Download

    [WORKSHOP B] - FULL DETAILS

    Download

    [DAY 1] - FULL PROGRAMME

    Download

    [WORKSHOP A] - FULL DETAILS

    Download

    [FULL BROCHURE] - 2018

    Download

    [PRESS RELEASE 1] - Discover the World of ATMPs

    Download

    Media Partners


    Labiotech.eu

    Supporters
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    EIN News

    Supporters
    http://www.einnews.com

    EIN News is the world leader in industry focused online news monitoring. Thousands of leading companies, institutions and global professionals from business, industry, and government rely on EIN News as an indispensable resource. Our systems continuously scan the web, indexing news from thousands of worldwide sources. The news you need is then organized by advanced software systems managed by a team of professional news editors. Everything we do is focused on streamlining your news searches and research in order to save you time and money.


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    ASD MEDIA

    Supporters
    http://www.asd-network.com

    Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
    • Be informed on the latest market developments; www.asd-network.com
    • Find the latest business news; www.asd-network.com
    • Find the upcoming events; www.asd-network.com
    • Find companies and organizations; www.asdsource.com
    • Distribute news globally. www.asdwire.com
    The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

    For more detailed information please contact with: ASD MEDIA
    Stefan.koopman@asdmedia.nl


    Gene Therapy Net

    Supporters
    http://www.genetherapynet.com

    Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Journal for Clinical Studies – Your Resource for Multisite Studies & Emerging Markets

    Supporters
    http://www.JforCS.com

    Published bi-monthly.JCS is a unique journal, dedicated to providing information to the global pharmaceutical, biotechnology, medical devices and contract research organisations. JCS details practical and theoretical operational procedures, challenges, validatory and regulatory guidelines when conducting trials on a multisite basis and particularly within the emerging markets, naïve patient population, and remote access areas. JCS provides country by country objectives and uniquely brings you experiences in therapeutic areas of Liver diseases, kidney diseases, insect borne diseases, malnutrition and under nutrition. JCS is led by a strong editorial advisory board sourced out for their experiences; you will get the most practical insight for your global studies. JCS invites you to join us, write for us, feature your experiences with us, advertise your capabilities with us, and ask our advisory board for suggestions and guidelines. Let us make health care available to all.


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    World Pharma News

    Supporters
    http://www.worldpharmanews.com/


    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.